Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine ...

Pfizer Inc says its experimental COVID-19 vaccine is more than 90 percent effective, a major victory in the fight against a pandemic that has killed more than a million people, battered the world’s ...

May 20 (Reuters) - Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune ...

Pfizer (PFE) stock is in focus as the company starts Phase 3 infant trials for the 25-valent pneumococcal vaccine after ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

A rare hantavirus outbreak on an Atlantic cruise ship has reignited conspiratorial Covid-era misinformation, with posts ...

Pfizer (PFE) is back in focus after two R&D milestones, a broader European indication for hemophilia drug HYMPAVZI and positive Phase 2 data for its 25 valent pneumococcal vaccine in infants, sparked ...

Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study ( NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent ...

The following companies are leading this vector-borne boon, each tackling the problem from a different technological angle: ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...

For the second time in as many weeks, there is promising news from the race for a COVID-19 vaccine as infections surge across the United States and Europe. US biotech firm Moderna Inc on Monday said ...